摘要
目的:探讨贝伐珠单抗(BEV)腹腔热灌注联合化疗对晚期卵巢癌患者血清肿瘤标志物水平的影响。方法:选择2020年1月至2021年12月于赣州市妇幼保健院治疗的86例卵巢癌患者,按随机数字表法将其分为两组,各43例。对照组采用紫杉醇联合顺铂(TP)化疗方案治疗,观察组于对照组基础上采用BEV腹腔热灌注治疗。比较两组临床疗效、血清肿瘤标志物、生存质量及不良反应。结果:观察组治疗疾病控制率(DCR)(83.72%)高于对照组(62.79%),治疗后癌抗原125(CA125)(51.16±12.75)kU/L、癌胚抗原(CEA)(13.39±4.08)ng/mL、血管内皮生长因子(VEGF)(30.57±6.98)ng/L低于对照组(60.57±14.02)kU/L、(17.02±5.41)ng/mL、(37.71±8.63)ng/L,KPS评分(75.96±7.22)分高于对照组(71.15±5.24)分,差异有统计学意义(P<0.05);两组恶心/呕吐、骨髓抑制、腹痛腹泻、肝肾功能损害、白细胞下降发生率比较,差异无统计学意义(P>0.05)。结论:晚期卵巢癌患者采用BEV腹腔热灌注、TP化疗联合应用可增强卵巢癌治疗效果,有利于降低CA125、CEA、VEGF水平,且不良反应并未增加,可促使患者生存质量得以提高。
Objective:To investigate bevacizumab(BEV)effects of intraperitoneal hyperthermic perfusion combined with chemotherapy on serum tumor marker levels in patients with advanced ovarian cancer.Methods:A total of 86 ovarian cancer patients who were treated in Ganzhou Maternal and Child Health Hospital from January 2020 to December 2021 were selected and divided into two groups according to the random number table method,with 43 cases in each group.The control group was treated with paclitaxel combined with cisplatin(TP)chemotherapy,and on the basis of the control group,the observation group was treated with BEV intraperitoneal hyperthermia.The clinical efficacy,serum tumor markers,quality of life and adverse reactions were compared between the two groups.Results:The disease control rate(DCR)(83.72%)in the observation group was higher than that in the control group(62.79%).After treatment,cancer antigen 125(CA125)(51.16±12.75)KU/L,carcinoembryonic antigen(CEA)(13.39±4.08)ng/mL,vascular endothelial growth factor(VEGF)(30.57±6.98)ng/L lower than the control group(60.57±14.02)KU/L,(17.02±5.41)ng/mL,(37.71±8.63)ng/L,KPS score(75.96±7.22)was higher than that of the control group(71.15±5.24),the difference was statistically significant(P<0.05).There was no significant difference between the two groups in the incidence of nausea/vomiting,bone marrow suppression,abdominal pain and diarrhea,liver and kidney function damage,and leukopenia(P>0.05).Conclusion:The combined application of BEV intraperitoneal hyperthermia and TP chemotherapy in patients with advanced ovarian cancer can enhance the therapeutic effect of ovarian cancer,which is beneficial to reduce the levels of CA125,CEA and VEGF,and the adverse reactions are not increased,which can improve the quality of life of patients.
作者
肖春晖
邱梅英
李静文
卢辛辛
XIAO Chunhui;QIU Meiying;LI Jingwen;LU Xinxin(Ganzhou Maternal and Child Health Hospital,Ganzhou Jiangxi,341000,China)
出处
《药品评价》
CAS
2022年第20期1260-1262,共3页
Drug Evaluation
关键词
卵巢肿瘤
高温
诱发
癌胚抗原
CA-125抗原
贝伐珠单抗腹腔热灌注
化疗
Ovarian neoplasms
Hyperthermia,induced
Carcinoembryonic antigen
CA-125 Antigen
Bevacizumab intraperitoneal hyperthermia
Chemotherapy
